Treatment of multicentric reticulohistiocytosis with adalimumab, minocycline, methotrexate

被引：12
|
作者：
Yeter, Karen C. [1 ]
Arkfeld, Daniel G. [1 ]
机构：
[1] Univ So Calif, Keck Sch Med, Dept Med Rheumatol, Los Angeles, CA 90033 USA
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2013年 / 16卷 / 01期
关键词：
ARTHRITIS;
D O I：
10.1111/j.1756-185X.2012.01762.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [41] Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
    Gisondi, Paolo
    Geat, Davide
    Armeni, Patrizio
    Bellinato, Francesco
    Maurelli, Martina
    Girolomoni, Giampiero
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1579 - 1584
  • [42] A Case with Familial Mediterranean Fever which Responds Well to Adalimumab Treatment
    Ortancil, Ozgur
    Sanli, Aslan
    Bulmus, Perihan Sapmaz
    Sarikaya, Selda
    TURKISH JOURNAL OF RHEUMATOLOGY, 2011, 26 (02) : 158 - 162
  • [43] Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab"
    Ortiz-Fernandez, Patricia
    Iniesta-Navalon, Carles
    Urbieta-Sanz, Elena
    Gascon-Canovas, Juan Jose
    CLINICAL RHEUMATOLOGY, 2025, 44 (03) : 1009 - 1018
  • [44] Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
    Bonafede, Machaon
    Johnson, Barbara H.
    Fox, Kathleen M.
    Watson, Crystal
    Gandra, Shravanthi R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (05) : 369 - 373
  • [45] Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
    Strober, Bruce E.
    Poulin, Yves
    Kerdel, Francisco A.
    Langley, Richard G.
    Gu, Yihua
    Gupta, Shiraz R.
    Okun, Martin M.
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (04) : 671 - 681
  • [46] Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study
    Asahina, Akihiko
    Torii, Hideshi
    Ohtsuki, Mamitaro
    Tokimoto, Toshimitsu
    Hase, Hidenori
    Tsuchiya, Tsuyoshi
    Shinmura, Yasuhiko
    Servin, Ofelia Reyes
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2016, 43 (11) : 1257 - 1266
  • [47] Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
    Campanilho-Marques, Raquel
    Deakin, Claire T.
    Simou, Stefania
    Papadopoulou, Charalampia
    Wedderburn, Lucy R.
    Pilkington, Clarissa A.
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [48] Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population
    Chastek, Benjamin
    Fox, Kathleen M.
    Watson, Crystal
    Kricorian, Gregory
    Gandra, Shravanthi R.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (01) : 25 - 33
  • [49] Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment
    Werner de Castro, Glaucio Ricardo
    Neves, Fabricio Souza
    Pereira, Ivanio Alves
    Magalhaes Souza Fialho, Sonia Cristina
    Ribeiro, Giovana
    Zimmermann, Adriana Fontes
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (05) : 1313 - 1316
  • [50] Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
    Gisondi, Paolo
    Geat, Davide
    Maurelli, Martina
    Degli Esposti, Luca
    Bellinato, Francesco
    Girolomoni, Giampiero
    VACCINES, 2022, 10 (05)
12345